Time of Day as an Unmeasured Confounder in Oncology Trials
Somer, J.; Benor, G.; Alpert, A.; Perets, R.; Mannor, S.
Show abstract
A recent randomized clinical trial in non-small cell lung cancer1 confirms what numerous observational studies have reported - time-of-day (ToD) may dramatically influence treatment outcomes in cancer patients2-9. In this recent trial median overall survival (OS) decreased from 28 months in the early ToD arm to 16.8 months in the late ToD arm. We raise the concern that clinical trial outcomes may be influenced by seemingly minor biases in treatment time across arms. We also suggest that by measuring or randomizing treatment-time in clinical trials, we may identify beneficial ToD-dependent treatments that would otherwise be overlooked.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies 92%
- A circuit mechanism for irrationalities in decision-making and NMDA receptor hypofunction: behaviour, computational modelling, and pharmacology 92%
- Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics and treatment regimens 92%
Similar papers in this journal
- A Standardized Metric to Enhance Clinical Trial Design and Outcome Interpretation in Type 1 Diabetes 93%
- Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials 93%
- Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 92%
Similar papers in this journal
- Additivity predicts the efficacy of most approved combination therapies for advanced cancer 96%
- Clinical interpretation of integrative molecular profiles to guide precision cancer medicine 93%
- Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence 91%
Similar papers in this journal
- Network and pathway expansion of genetic disease associations identifies successful drug targets 92%
- Interpretable Deep Learning for Improving Cancer Patient Survival Based on Personal Transcriptomes 92%
- Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.